$OKLO

Oklo (OKLO) shares fell 6.8% to $27.97 on October 16, down 61% YTD. Analysts' average price target is $75.38, implying 170% upside. Oklo launched a $1B equity offering, raising dilution concerns. The company has $3B in cash but faces rising development costs. Analysts' targets range from $14 to $130, reflecting uncertainty about commercialization timelines and financing needs.

Nuclear energy stocks have dropped significantly over the past year, with the Global X Uranium ETF (URA) down over 20%. Specific companies like NuScale Power (SMR), Oklo (OKLO), and Nano Nuclear (NNE) have seen steep declines, despite advancements in technology and partnerships. Investors are concerned about long timelines and lack of commercial revenues.

Oklo Inc.'s CPO Alexandra Renner sold 688 shares for $21,156 on Oct 14 to cover tax obligations. Oklo's stock has fallen 13.5% in a week, but analysts see undervaluation. The company's market cap is $5.58B. Oklo launched a $1B stock offering program. Analysts have mixed ratings and price targets, ranging from $41 to $100.

NuScale Power (SMR) fell 7% to $6.04, Energy Fuels (UUUU) dropped 9% to $8.43, and Oklo (OKLO) slid 5% to $30.11 as 10-year Treasury yields rose to 5.26%. The Global X Uranium ETF (URA) declined 4%, outpacing the broader market's 0.8% drop. Rising yields impact long-duration assets like nuclear developers, affecting both valuation and project financing costs.

Oklo (NYSE: OKLO), a nuclear energy company, launched a $1 billion stock sale on Sept. 11, adding to prior sales since its May 2024 SPAC merger. Outstanding shares increased 58% to 192.3 million, diluting early shareholders by 37%. Despite a 311% share price increase, Oklo's stock hit a 52-week low on Oct. 8, requiring more shares to raise the same capital.

Alphabet (GOOG, GOOGL) agreed to a 15-year and 20-year deal with Constellation Energy (CEG) for nuclear power, investing $4.3B in new capacity. Oklo (OKLO) and NuScale (SMR) shares also rose, despite no direct involvement. The companies develop small modular reactors (SMRs) for specific facilities, differing from Constellation's large-scale plants. Investors see broader nuclear energy growth, with SMRs expected to play a significant role by 2050, according to industry estimates.

Oklo Inc. is advancing its Groves-1 Isotope Test Reactor in Texas, which has cleared regulatory milestones and achieved first criticality. The facility supports isotope development for medical, scientific, and security uses. Oklo received enriched ytterbium-176 for cancer treatment production, aiming to reduce overseas reliance. The company plans to expand its isotope business, with potential commercial revenue from its Idaho lab.

Oklo, a modular nuclear reactor company, focuses on selling long-term electricity contracts. It secured NRC approval for its Aurora design, has $1.6B cash, and partnerships with NVDA, META, and Switch. However, it reports $33M net loss, no revenue, and no operating plants. Market cap is $11B. Regulatory hurdles remain.

Oklo Inc. (NYSE: OKLO) will advance its Groves 2 Forge isotope production facility as part of the U.S. Department of Energy's Nuclear Energy Launch Pad initiative. The project builds on the company's Groves Isotope Test Reactor experience, adding capabilities to produce, process, and purify critical isotopes.

Oklo Inc. shares fell 6.11% to a 52-week low on October 8, closing at $34.57. The nuclear developer's market cap is $6.43B, with an enterprise value of $3.97B. Investors are assessing risks related to its reactor projects, funding needs, and path to commercial power generation. Oklo is targeting small modular reactors (SMRs) for clean energy, but a study warns of potential uneconomical operating costs.